Covered recipient · General Payments record
MICHAEL A TELLEZ
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$1,100.32
- Reported across 52 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $637.01 | 28 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $156.99 | 5 |
| ABBVIE INC. | $154.18 | 7 |
| Novo Nordisk AS | $107.75 | 6 |
| Astellas Pharma US Inc | $45.89 | 2 |
| Galderma Laboratories, L.P. | $37.65 | 2 |
| Neurelis, Inc. | $28.27 | 1 |
| Janssen Pharmaceuticals, Inc | $28.02 | 1 |
| REVANCE THERAPEUTICS, INC. | $23.47 | 1 |
| Braeburn Inc. | $22.19 | 1 |
| FIDIA PHARMA USA INC. | $18.37 | 1 |
| Acerta Pharma LLC | $14.23 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (28)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $34.20 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294678 | CMS |
| ABBVIE INC. | $33.30 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294680 | CMS |
| ABBVIE INC. | $24.83 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294682 | CMS |
| ABBVIE INC. | $4.54 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294684 | CMS |
| ABBVIE INC. | $18.75 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294686 | CMS |
| ABBVIE INC. | $33.94 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294688 | CMS |
| ABBVIE INC. | $4.62 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108294690 | CMS |
| Astellas Pharma US Inc | $24.88 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139519953 | CMS |
| Astellas Pharma US Inc | $21.01 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139535420 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.23 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105470203 | CMS |
| Braeburn Inc. | $22.19 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125619256 | CMS |
| Fidia Pharma USA Inc. | $18.37 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141160875 | CMS |
| Galderma Laboratories, L.P. | $22.59 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145396069 | CMS |
| Galderma Laboratories, L.P. | $15.06 | 08/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145396071 | CMS |
| Janssen Pharmaceuticals, Inc | $28.02 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078203573 | CMS |
| Lilly USA, LLC | $23.82 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135832151 | CMS |
| Lilly USA, LLC | $102.99 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135822218 | CMS |
| Lilly USA, LLC | $0.41 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135845310 | CMS |
| Lilly USA, LLC | $8.66 | 07/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135758384 | CMS |
| Lilly USA, LLC | $21.11 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135791458 | CMS |
| Neurelis, Inc. | $28.27 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145671440 | CMS |
| Novo Nordisk Inc | $15.26 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100294986 | CMS |
| Novo Nordisk Inc | $19.65 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100478008 | CMS |
| Novo Nordisk Inc | $20.80 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100258532 | CMS |
| Novo Nordisk Inc | $18.30 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100603796 | CMS |
| Novo Nordisk Inc | $13.44 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100612158 | CMS |
| Novo Nordisk Inc | $20.30 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100310811 | CMS |
| REVANCE THERAPEUTICS, INC. | $23.47 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147952118 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.